Cargando…
Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
Recombinant Towne CMV expressing luciferase under the control of CMV-DNA polymerase (POL) or the late pp28 (UL99) promoters were evaluated for potential application in high-throughput screening of anti-viral compounds. POL-and pp28-luciferase displayed maximal expression 48 and 72 hours post infecti...
Autores principales: | He, Ran, Sandford, Gordon, Hayward, Gary S, Burns, William H, Posner, Gary H, Forman, Michael, Arav-Boger, Ravit |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041771/ https://www.ncbi.nlm.nih.gov/pubmed/21269468 http://dx.doi.org/10.1186/1743-422X-8-40 |
Ejemplares similares
-
An Artemisinin-Derived Dimer Has Highly Potent Anti-Cytomegalovirus (CMV) and Anti-Cancer Activities
por: He, Ran, et al.
Publicado: (2011) -
Detection of a Single Identical Cytomegalovirus (CMV) Strain in Recently Seroconverted Young Women
por: Murthy, Suchetha, et al.
Publicado: (2011) -
Prevalence, Magnitude, and Genotype Distribution of Urinary Cytomegalovirus (CMV) Shedding Among CMV-Seropositive Children and Adolescents in the United States
por: White, Jodie L, et al.
Publicado: (2019) -
The Use of Artificial Neural Networks in Prediction of Congenital CMV Outcome from Sequence Data
por: Arav-Boger, Ravit, et al.
Publicado: (2008) -
Blood Viral Load (VL) Not Clinically Meaningful in Symptomatic Congenital Cytomegalovirus (cCMV) Infection
por: Marsico, Concetta, et al.
Publicado: (2017)